{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:47:06Z","timestamp":1768265226795,"version":"3.49.0"},"reference-count":353,"publisher":"Elsevier","isbn-type":[{"value":"9780443238321","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.pmbts.2024.12.002","type":"book-chapter","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T20:03:56Z","timestamp":1738440236000},"page":"73-133","source":"Crossref","is-referenced-by-count":2,"title":["Immunobiology and immunotherapy of COVID-19"],"prefix":"10.1016","author":[{"given":"Kenneth","family":"Lundstrom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/bs.pmbts.2024.12.002_bib1","unstructured":"COVID \u2013 Coronavirus Statistics. \u3008www.worldometers.info\/coronavirus\/\u3009 (accessed on June 7, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib2","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMc2009324","article-title":"Droplets and aerosols in the transmission of SARS\u2010 CoV","volume":"382","author":"Meselson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","article-title":"Evolution of the novel corona. Virus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","volume":"63","author":"Xu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.coph.2006.03.001","article-title":"Angiotensin\u2010converting enzyme 2 in lung diseases","volume":"6","author":"Kuba","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin\u2010converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ccc.2021.05.003","article-title":"Pathophysiology of acute respiratory distress syndrome and COVID-19 lung injury","volume":"37","author":"Swenson","year":"2021","journal-title":"Crit Care Clin"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID\u201019) from publicly reported confirmed cases: estimation and application","volume":"172","author":"Lauer","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/jir.2020.0210","article-title":"Role of host immune and inflammatory responses in COVID-19 cases with underlying primary immunodeficiency: a review","volume":"40","author":"Liu","year":"2020","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID\u201019","volume":"10","author":"Li","year":"2020","journal-title":"J Pharm Anal"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-020-0732-3","article-title":"Immune\u2010mediated approaches against COVID\u201019","volume":"15","author":"Florindo","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Antiviral activities of type I interferons to SARS\u2010CoV\u20102 infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.6026\/97320630016219","article-title":"CoViD\u201019 immunopathology and immunotherapy","volume":"16","author":"Chiappelli","year":"2020","journal-title":"Bioinformation"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib14","doi-asserted-by":"crossref","first-page":"ix","DOI":"10.1016\/S1937-6448(19)30095-4","article-title":"Preface-dendritic cells: master regulators of innate and adaptive immunity","volume":"348","author":"Lhuillier","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib15","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/gt.2009.92","article-title":"Immune responses to T\u2010cell epitopes of SARS CoV\u2010N protein are enhanced by N immunization with a chimera of lysosome\u2010associated membrane protein","volume":"16","author":"Yang","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID\u201019","volume":"10","author":"Li","year":"2020","journal-title":"J Pharm Anal"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib17","doi-asserted-by":"crossref","first-page":"10464","DOI":"10.1128\/JVI.05039-11","article-title":"Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope","volume":"85","author":"Chia","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"TH17 responses in cytokine storm of COVID\u201019: an emerging target of JAK2 inhibitor fedratinib","volume":"53","author":"Wu","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1148\/radiol.2020200463","article-title":"Chest CT findings in coronavirus disease\u201019 (COVID\u201019): relationship to duration of infection","volume":"295","author":"Bernheim","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.coviro.2012.04.004","article-title":"SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon","volume":"2","author":"Totura","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/nsr\/nwaa041","article-title":"Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID\u201019 patients","volume":"7","author":"Zhou","year":"2020","journal-title":"Natl Sci Rev"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib22","first-page":"1022","article-title":"Associations between immune\u2010suppressive and stimulating drugs and novel COVID\u201019\u2014a systematic review of current evidence","volume":"14","author":"Russell","year":"2020","journal-title":"E Cancer Med Sci"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID\u201019)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib24","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/annrheumdis-2020-217424","article-title":"Clinical course of COVID\u201019 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies","volume":"79","author":"Monti","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41577-020-0360-z","article-title":"Immune evasion via SARS\u2010CoV\u20102 ORF8 protein?","volume":"20","author":"Park","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.immuni.2020.07.005","article-title":"Lessons for COVID\u201019 immunity from other coronavirus infections","volume":"53","author":"Sariol","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib27","first-page":"1","article-title":"Immune responses in COVID\u201019 and potential vaccines: lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib28","series-title":"Coronavirus Disease 2019 (COVID\u201019), Medical Virology: From Pathogenesis to Disease Control","first-page":"43","article-title":"Host immune response and immunobiology of human SARS\u2010CoV\u20102 infection","author":"Kumar","year":"2020"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib29","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID\u201019: current state of the science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib30","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.5858\/arpa.2020-0471-SA","article-title":"Predicting disease severity and outcome in COVID\u201019 patients: a review of multiple biomarkers","volume":"144","author":"Tjendra","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID\u201019)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib32","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/jcp.30076","article-title":"Immunobiology and immunotherapy of COVID-19: a clinically updated overview","volume":"236","author":"Esmaeilzadeh","year":"2021","journal-title":"J Cell Physiol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib33","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12015-019-09901-7","article-title":"Solid tumors challenges and new insights of car t cell engineering","volume":"15","author":"Tahmasebi","year":"2019","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib34","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2217\/imt.09.26","article-title":"Immunotherapy of viral infections","volume":"1","author":"Hegde","year":"2009","journal-title":"Immunotherapy"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107245","article-title":"Interferon-inducer antivirals: potential candidates to combat COVID-19","volume":"91","author":"Bagheri","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib36","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta\u20101b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID\u201019: an open\u2010label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/jmv.27317","article-title":"The role of type I interferon in the treatment of COVID-19","volume":"94","author":"Sodeifian","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib38","article-title":"Umifenovir in hospitalized moderate to severe COVID-19 patients: a randomized clinical trial","volume":"99","author":"Darazam","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib39","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3389\/fimmu.2020.01061","article-title":"Interferon-alpha2b treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib40","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa2209760","article-title":"Early treatment with pegylated interferon lambda for Covid-19","volume":"388","author":"Reis","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib41","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS\u2010CoV\u20102 in patients with COVID\u201019","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib42","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib43","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib44","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1080\/23744235.2021.1940271","article-title":"Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients \u2013 a safe but futile intervention. A comparative cohort study","volume":"53","author":"Hoepler","year":"2021","journal-title":"Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib45","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/life13122322","article-title":"The role of convalescent plasma in COVID-19: a conclusive post-pandemic review","volume":"13","author":"Franchini","year":"2023","journal-title":"Life"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib46","article-title":"Covid\u201019: FDA approves use of convalescent plasma to treat critically ill patients","volume":"368","author":"Tanne","year":"2020","journal-title":"Br Med J"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib47","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","article-title":"Monoclonal antibody therapies against SARS-CoV-2","volume":"22","author":"Focosi","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib48","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus\u2010specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib49","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib50","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl Med J"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2402","article-title":"Efficacy and safety of sotrovimab in patients with COVID-19: a rapid review and meta-analysis","volume":"32","author":"Amani","year":"2022","journal-title":"Rev Med Virol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib52","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40265-022-01690-7","article-title":"Sotrovimab: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/v16020217","article-title":"Sotrovimab: a review of its efficacy against SARS-CoV-2 variants","volume":"16","author":"Focosi","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib54","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1854149","article-title":"Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline","volume":"12","author":"Tuccori","year":"2020","journal-title":"MABS"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib55","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib56","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/cpt.2405","article-title":"First-in-human study of bamlanivimab in a randomized trial of hospitalized patients with COVID-19","volume":"110","author":"Chen","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib58","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib59","unstructured":"Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19. FDA Official Website, 2020, https:\/\/www.fda.gov\/news-events\/press-announcements\/corona-virus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19 (accessed on March 1, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib60","unstructured":"Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab. www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab (accessed on March 4, 2023)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib61","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical tial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib62","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimab in mild or moderate Covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib63","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/22221751.2022.2032374","article-title":"Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib64","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ijid.2022.06.045","article-title":"Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19","volume":"122","author":"Isa","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101102","article-title":"Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19","volume":"40","author":"Razonable","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib66","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s40265-021-01620-z","article-title":"Casirivimab\/imdevimab: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib67","doi-asserted-by":"crossref","first-page":"eabl8124","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib68","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib69","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/14787210.2022.2134118","article-title":"Tixagevimab\/cilgavimab for prevention and treatment of COVID-19: a review","volume":"20","author":"Ustianowski","year":"2022","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib70","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40265-022-01731-1","article-title":"Tixagevimab + cilgavimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101832","article-title":"SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial","volume":"57","author":"Vega","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib73","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.3390\/ijms21072272","article-title":"Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID\u201019 and strengthen the immune system of new patients?","volume":"21","author":"Jawhara","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa102","article-title":"High\u2010dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019","volume":"7","author":"Cao","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2397","article-title":"Intravenous immunoglobulin (IVig) therapy in hospitalized adult COVID-19 patients: a systematic review and meta-analysis","volume":"32","author":"Marcec","year":"2022","journal-title":"Rev Med Virol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib76","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL\u20106 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib77","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1186\/s12879-020-05701-4","article-title":"Effects of Tocilizumab in COVID-19 patients: a cohort study","volume":"20","author":"Vu","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib78","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/14787210.2023.2226867","article-title":"Tocilizumab for the treatment of COVID-19","volume":"21","author":"Flisiak","year":"2023","journal-title":"Exp Rev Anti-Infect Ther"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib79","first-page":"113","article-title":"for tocilizumab (Actemra) for COVID-19. (No authors listed)","volume":"63","author":"An","year":"2021","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib80","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1136\/annrheumdis-2020-218122","article-title":"Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study","volume":"79","author":"Della-Torre","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib81","doi-asserted-by":"crossref","first-page":"8903435","DOI":"10.1155\/2021\/8903435","article-title":"Efficacy and safety of sarilumab in COVID-19: a systematic review","volume":"2021","author":"Chamlagain","year":"2021","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib82","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib83","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib84","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40001-023-01072-z","article-title":"Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis","volume":"28","author":"Dahms","year":"2023","journal-title":"Eur J Med Res"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib85","first-page":"e203","article-title":"for anakinra (Kineret) for COVID-19. (No authors listed)","volume":"64","author":"An","year":"2022","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib86","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/iid3.400","article-title":"Efficacy of canakinumab in mild or severe COVID-19 pneumonia","volume":"9","author":"Falasca","year":"2021","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib87","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1164\/rccm.201410-1782OC","article-title":"Innate lymphoid cells are the predominant source of IL\u201017A during the early pathogenesis of acute respiratory distress syndrome","volume":"193","author":"Muir","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155627","article-title":"Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: a pilot study","volume":"146","author":"Avdeev","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib89","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/ijp.IJP_615_20","article-title":"Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistnat to anakinra, tocilizumab, and Janus kinase inhibitors?","volume":"53","author":"Cure","year":"2021","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib90","unstructured":"Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. https:\/\/clinicaltrials.gov\/show\/NCT04324021, 2020 (accessed on April 11, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib91","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1097\/CCM.0000000000005683","article-title":"Avdoralimab (anti-C5aR1 mAb) versus placebo in patients with severe COVID-19: Results from a randomized controlled trial (FOR COVID elimination [FORCE])","volume":"50","author":"Carvelli","year":"2022","journal-title":"Crit Care Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib92","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12931-022-02126-2","article-title":"Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial","volume":"23","author":"De Leeuw","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(23)00082-6","article-title":"Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial","volume":"11","author":"Annane","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib94","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S2213-2600(23)00376-4","article-title":"Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial","volume":"11","author":"Hall","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108450","article-title":"The first case of COVID-19 treated with the complement C3 inhibitor AMY-101","volume":"215","author":"Mastaglio","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib96","doi-asserted-by":"crossref","first-page":"eabo2341","DOI":"10.1126\/sciadv.abo2341","article-title":"Complement C3 inhibition in severe COVID-19 using compstatin AMY-101","volume":"8","author":"Skendros","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-015-0461-y","article-title":"Anti\u2010inflammatory effects of dexamethasone and meloxicam on Borrelia burgdorferi\u2010induced inflammation in neuronal cultures of dorsal root ganglia and myelinating cells of the peripheral nervous system","volume":"12","author":"Ramesh","year":"2015","journal-title":"J Neuroinflammation"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173947","article-title":"No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomized clinical trial","volume":"897","author":"Jamaati","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib99","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib100","first-page":"1241","article-title":"Dexamethasone for COVID-19? Not so fast","volume":"34","author":"Theoharides","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252057","article-title":"Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia","volume":"16","author":"Pinzon","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib102","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00134-021-06394-2","article-title":"Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis","volume":"47","author":"Chaudhuri","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib103","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3389\/fimmu.2018.01717","article-title":"Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells","volume":"9","author":"Elahi","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib104","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13287-020-01699-3","article-title":"Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus\u2010 induced acute lung injury","volume":"11","author":"Du","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib105","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3389\/fimmu.2017.01770","article-title":"Mesenchymal stromal\/stem cells: a new era in the cell\u2010based targeted gene therapy of cancer","volume":"8","author":"Marofi","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib106","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14336\/AD.2020.0228","article-title":"Transplantation of ACE2\u2010 mesenchymal stem cells improves the outcome of patients with COVID\u201019 pneumonia","volume":"11","author":"Leng","year":"2020","journal-title":"Aging Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib107","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3390\/cells9040924","article-title":"Mesenchymal stromal cell secretome for severe COVID\u201019 infections: premises for the therapeutic use","volume":"9","author":"Bari","year":"2020","journal-title":"Cells"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109769","article-title":"Mesenchymal stem cell (MSc) secretome: a possible therapeutic strategy for intensive\u2010care COVID\u201019 patients","volume":"142","author":"Deffune","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib109","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13287-022-02771-w","article-title":"Safety and efficacy study of allogenic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II","volume":"13","author":"Fathi-Kazerooni","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib110","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s41590-018-0163-6","article-title":"Natural killer cell specificity for viral infections","volume":"19","author":"Hammer","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e07635","article-title":"Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19","volume":"7","author":"Jeyaraman","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib112","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40814-023-01355-6","article-title":"Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19","volume":"9","author":"Ahmadvand","year":"2023","journal-title":"Pilot Feasibility Stud"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib113","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12015-019-09901-7","article-title":"Solid tumors challenges and new insights of car t cell engineering","volume":"15","author":"Tahmasebi","year":"2019","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib114","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1038\/s41467-022-30216-8","article-title":"Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19","volume":"13","author":"Lu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.652223","article-title":"CAR-NK cells effectively target SARS-CoV-2-spike-expressing cell lines in vitro","volume":"12","author":"Ma","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib116","unstructured":"A Phase I\/II Study of Universal Off-the-shell NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19. https:\/\/clinicaltrials.gov\/show\/NCT04324996, 2020 (accessed on April 17, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib117","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2147\/DDDT.S347297","article-title":"Immunotherapy and CRISPR cas systems: potential cure of COVID-19?","volume":"16","author":"He","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib118","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.immuni.2020.07.009","article-title":"Single\u2010cell sequencing of peripheral blood mononuclear cells reveals distinct immune response landscapes of COVID\u201019 and influenza patients","volume":"53","author":"Zhu","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib119","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.bbmt.2020.04.008","article-title":"CAR T cell therapy during the COVID\u201019 pandemic","volume":"26","author":"Bachanova","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib120","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/imm.13432","article-title":"Identifying SARS-CoV-2 \u201cmemory\u201d NK cells from COVID-19 convalescent donors for adoptive cell therapy","volume":"165","author":"Herrera","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101086","article-title":"Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)","volume":"39","author":"Perez-Martinez","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib122","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jcyt.2023.10.002","article-title":"Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and\/or lymphopenia (RELEASE NCT04578210)","volume":"26","author":"Ferreras","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib123","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1038\/s41467-019-12321-3","article-title":"CAR exosomes derived from effector CAR\u2010T cells have potent antitumour effects and low toxicity","volume":"10","author":"Fu","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108708","article-title":"SARS-CoV-2 antigen-carrying extracellular vesicles activate T cell responses in a human immunogenicity model","volume":"27","author":"Cummings","year":"2024","journal-title":"iScience"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.785941","article-title":"Exosomes recovered from the plasma of COVID-19 patients expose SARS-CoV-2 spike-derived fragments and contribute to the adaptive immune response","volume":"12","author":"Pesce","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib126","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib127","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib128","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146701","article-title":"PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response","volume":"6","author":"Loretelli","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib129","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1016\/j.vaccine.2023.06.053","article-title":"PD-1\/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness","volume":"41","author":"Chen","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111957","article-title":"Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection","volume":"142","author":"Awadasseid","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib131","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41423-020-0450-7","article-title":"NKG2A and COVID\u201019: another brick in the wall","volume":"17","author":"Antonioli","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID\u201019 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib133","doi-asserted-by":"crossref","first-page":"1022890","DOI":"10.3389\/fimmu.2023.1022890","article-title":"NK cells from COVID-19 positive patients exhibit cytotoxic activity upon NKG2A and KIR2DL blockade","volume":"14","author":"Lee","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib134","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID\u201019: current state of the science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib135","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/vaccines8020224","article-title":"Recent insight into SARS\u2010CoV2 immunopathology and rationale for potential treatment and preventive strategies in COVID\u201019","volume":"8","author":"Lega","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib136","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/14760584.2022.2110076","article-title":"Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management","volume":"21","author":"Chavda","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.989685","article-title":"Developing dendritic cell for SARS-CoV-2 vaccine: breakthrough in the pandemic","volume":"13","author":"Jonny","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib138","doi-asserted-by":"crossref","first-page":"1122389","DOI":"10.3389\/fimmu.2023.1122389","article-title":"Safety and efficacy of dendritic cell vaccine for COVID-19 prevention after 1-Year follow-up: phase I and II clinical trial final result","volume":"14","author":"Jonny","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib139","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID\u201019: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib141","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1473-3099(20)30262-0","article-title":"Baricitinib for COVID\u201019: a suitable treatment?","volume":"20","author":"Favalli","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib142","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019\u2010 nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib143","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/vaccines4030023","article-title":"Viral inhibition of the IFN\u2010induced JAK\/STAT signalling pathway: development of live attenuated vaccines by mutation of viral\u2010encoded IFN\u2010antagonists","volume":"4","author":"Fleming","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib144","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13063-021-05072-4","article-title":"A Phase I\/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onc-hematological patients affected with COVID-19: a structural summary of a study protocol for a randomised controlled trial","volume":"22","author":"Moreno-Gonz\u00e1lez","year":"2021","journal-title":"Trials"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib145","first-page":"11","article-title":"Mortality comparison in patients receiving either Remdesivir or Remdesivir plus Baricitinib combination in case of moderate to severe COVID-19 Pneumonia: a retrospective study","volume":"70","author":"Das","year":"2022","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib146","unstructured":"Stewart J. Olumiant FDA Approval History, www.drugs.com\/history\/olumiant.html (accessed on April 23, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib147","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/archsurg.134.10.1049","article-title":"Role of granulocyte\u2010macrophage colony\u2010stimulating factor and its receptor in the genesis of acute respiratory distress syndrome through an effect on neutrophil apoptosis","volume":"134","author":"Goodman","year":"1999","journal-title":"Arch Surg"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib148","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.mayocp.2020.08.038","article-title":"GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study","volume":"95","author":"Temesgen","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib149","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S2213-2600(21)00494-X","article-title":"Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial","volume":"10","author":"Temesgen","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib150","doi-asserted-by":"crossref","first-page":"2101870","DOI":"10.1183\/13993003.01870-2021","article-title":"A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)","volume":"61","author":"Patel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib151","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1164\/rccm.202108-1859OC","article-title":"Anti-granulosyte-macrophage colony-stimulating factor monoclonal antibody gimsilumab for COVID-19 pneumonia: a randomized double-blind placebo-controlled trial","volume":"205","author":"Criner","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib152","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2665-9913(20)30170-3","article-title":"GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study","volume":"2","author":"De Luca","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib153","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2665-9913(21)00070-9","article-title":"Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial","volume":"3","author":"Cremer","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib154","doi-asserted-by":"crossref","first-page":"e2629","DOI":"10.1093\/milmed\/usac362","article-title":"Inhaled sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor) for COVID-19-associated acute gypoxemia: results of the phase 2, randomized, open-label trial (iLeukPulm)","volume":"188","author":"Paine","year":"2022","journal-title":"Mil Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104902","article-title":"The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro","volume":"182","author":"Okamoto","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib156","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jgar.2022.12.004","article-title":"Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial","volume":"32","author":"Kurth","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib157","article-title":"Disruption of CCR5 signaling to treat cOVID-19-associated cytokine storm: case series of four critically treated with leronlimab","volume":"4","author":"Agresti","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib158","article-title":"Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab","volume":"4","author":"Elneil","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib159","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS\u2010CoV\u20102 pneumonia in Wuhan, China: a single\u2010centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib160","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41467-021-21085-8","article-title":"Efficacy and tolerability of bevacizumab in patients with severe Covid-19","volume":"12","author":"Pang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib161","doi-asserted-by":"crossref","first-page":"307","DOI":"10.14740\/jmc3948","article-title":"The impact on COVID-19 by intravenous bevacizumab used for hereditary hemorrhacig telangiectasia: a case report","volume":"13","author":"Fanning","year":"2022","journal-title":"J Med Cases"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib162","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3855\/jidc.15386","article-title":"The potential role of the combined PARP-1 and VEGF inhibitors in severe SARS-CoV-2 (COVID-19) infection","volume":"16","author":"Lampropoulou","year":"2022","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib163","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1038\/s41598-017-07397-0","article-title":"CD14 is critical for TLR2\u2010mediated M1 macrophage activation triggered by N\u2010glycan recognition","volume":"7","author":"Da Silva","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib164","article-title":"Report of the first seven agents in the I-SPY COVID trial: a phase 2, open-label, adaptive platform randomised controlled trial","volume":"58","year":"2023","journal-title":"EclinicalMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104667","article-title":"Phase 2, randomised, double-blind, placebo-controlled multi-center trial of the clinical and biological effects of anti-CD14 treatment in hospitalized patients with COVID-19 pneumonia","volume":"93","author":"Mabrey","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib166","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00066-012-0170-8","article-title":"Anti\u2010inflammatory effects of low\u2010dose radiotherapy","volume":"188","author":"Arenas","year":"2012","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib167","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4103\/jcrt.JCRT_1045_20","article-title":"Low-dose radiotehrapy for COVID-19: a radioimmunological perspective","volume":"17","author":"Kumar","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib168","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/09553002.2021.1864049","article-title":"Low-dose radiotherapy (LD-RT) for COVID-19-induced pneumopathy: a worth considering approach","volume":"97","author":"Koosha","year":"2021","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib169","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1007\/s00066-020-01675-z","article-title":"Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review","volume":"196","author":"Del Castillo","year":"2020","journal-title":"Strahlenther Onkol"},{"issue":"2021","key":"10.1016\/bs.pmbts.2024.12.002_bib170","first-page":"0187","article-title":"Low-dose radiation therapy for COVID-19 pneumonia: a pilot study","volume":"94","author":"Sharma","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110559","article-title":"COVID-19 signalome: potential therapeutic interventions","volume":"103","author":"Lundstrom","year":"2023","journal-title":"Cell Signal"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib172","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib173","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s00705-023-05881-9","article-title":"Molnupiravir: an antiviral drug against COVID-19","volume":"168","author":"Dave","year":"2023","journal-title":"Arch Virol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib174","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib175","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40265-022-01684-5","article-title":"Molnupiravir. First approval","volume":"82","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib176","doi-asserted-by":"crossref","first-page":"7341493","DOI":"10.1155\/2022\/7341493","article-title":"Paxlovid: mechanism of action, synthesis, and in silico study","volume":"2022","author":"Marzi","year":"2022","journal-title":"Biomed Res Int"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib177","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of paxlovid in reducing severe Coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib178","article-title":"Efficacy and safety of nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis","volume":"95","author":"Amani","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib179","first-page":"2118","article-title":"FDA grants full approval to paxlovid, COVID-19 antiviral treatment","volume":"329","author":"Harris","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib180","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/v16020203","article-title":"COVID-19 vaccines: Where did we stand at the end of 2023?","volume":"16","author":"Lundstrom","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib181","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24418","article-title":"An overview on inactivated and live-attenuated SARS-CoV-2 vaccines","volume":"36","author":"Khoshnood","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib182","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41598-021-04244-1","article-title":"The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates","volume":"12","author":"Al Kaabi","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib183","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1586\/erv.12.38","article-title":"Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges","volume":"11","author":"Delrue","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib184","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7150\/ijbs.52569","article-title":"Current advances in the development of SARS-CoV-2 vaccines","volume":"17","author":"Awadasseid","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib185","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3390\/v15091828","article-title":"Safety and immunogenicity of inactivated whole virion COVID-19 vaccine Covivac in clinical trials in 18-60 and 60+ age cohorts","volume":"15","author":"Gordeychuk","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib186","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib187","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomized, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib188","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1186\/s13063-020-04775-4","volume":"21","author":"Palacios","year":"2020","journal-title":"Trials"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib189","unstructured":"The WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations. www.who.int, June 1, 2021 (accessed May 21, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib190","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jinf.2022.06.009","article-title":"Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: a randomized, dose escalation, double-blind phase 1\/2 clinical trial in healthy adults","volume":"85","author":"Lazarus","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib191","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/S1473-3099(22)00502-3","article-title":"Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomized, controlled, phase 3, immunobridging trial","volume":"22","author":"Lazarus","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib192","unstructured":"Valneva Receives Emergency Use Authorization from Bahrain for its Inactivated COVID-19 Vaccine VLA 2001 (press release) www.valneva.com, (accessed May 21, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib193","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.vaccine.2022.10.093","article-title":"Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: interim results from randomized, double-blind, placebo-controlled phase 1 and 2 trials","volume":"41","author":"Ozdarendeli","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib194","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3390\/vaccines10111865","article-title":"Efficacy. Immunogenicity, and safety of the two-dose schedules of TURKOVAC versus coronavac in healthy subjects: a randomized, observer-blinded, non-inferiority phase III trial","volume":"10","author":"Tanriover","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib195","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/ofid\/ofac177","article-title":"Effectiveness of Coronavirus disease 2019 vaccines in preventing infection, hospital admission, and death: a historical cohort study using Iranian registration data during vaccination program","volume":"9","author":"Mirahmadizadeh","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib196","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib197","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomized, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101078","volume":"39","author":"Zakarya","year":"2021","journal-title":"EclinicalMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101526","article-title":"Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in\u00ae, in healthy adults: a multicentre, randomized, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up","volume":"50","author":"Khairullin","year":"2022","journal-title":"EclinicalMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib200","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"2020","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib201","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib202","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib203","unstructured":"Sinovac\u2019s coronavirus vaccine candidate approved for emergency use in China \u2013 source. Reuters. 29 August 2020. https:\/\/www.reuters. (accessed May 22, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib204","unstructured":"Taylor A. WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine\u201d. The Washington Post. May 7, 2021. (accessed May 22, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib205","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.927306","article-title":"A comprehensive review of the protein subunit vaccines against COVID-19","volume":"13","author":"Heidary","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib206","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1473-3099(21)00147-X","article-title":"Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomized, placebo-controlled, phase 1-2, dose-ranging study","volume":"21","author":"Goepfert","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib207","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1473-3099(21)00764-7","article-title":"Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomized, dose-finding, multicentre study","volume":"22","author":"Sridhar","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib208","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomized, double-blind, placebo-controlled trial","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib209","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.vaccine.2023.02.017","article-title":"Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-na\u00efve and exposed individuals in a phase 2\/3, double-blind, randomized study","volume":"41","author":"Buntinx","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib210","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1016\/j.vaccine.2022.04.041","article-title":"Covax-19\/Spikogen\u00ae vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single does protection against SASR-CoV-2 infection in hamsters","volume":"40","author":"Li","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib211","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cmi.2022.04.004","article-title":"Safety and immunogenicity of SpikoGen\u00ae, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations","volume":"28","author":"Tabarsi","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"2023","key":"10.1016\/bs.pmbts.2024.12.002_bib212","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2022.09.001","article-title":"Evaluating the efficacy and safety of SpikoGen\u00ae, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial","volume":"29","author":"Tabarsi","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib213","article-title":"Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: interim results of a double-blind, randomized controlled phase 1 and 2 trial","volume":"24","author":"Nguyen","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib214","article-title":"The efficacy, safety and immunogenicity of Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trial","author":"Nguyen","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib215","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1016\/j.xphs.2023.09.027","article-title":"Phase II, safety and immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 vaccine in adults aged 18-70 years; a randomized, double-blind clinical trial","volume":"112","author":"Mohazzab","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib216","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S2213-2600(21)00402-1","article-title":"Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomized, placebo-controlled phase 2 trial in Taiwan","volume":"9","author":"Hsieh","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib217","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.vaccine.2022.10.030","article-title":"An evaluation of the safety and immunogenicity of MVC-COV1901: results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay","volume":"41","author":"Torales","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib218","first-page":"5","article-title":"Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2","volume":"76","author":"Ryzhikov","year":"2021","journal-title":"Ann Russian Acad Med Sci"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib219","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/vaccines11050998","article-title":"Assessment of safety and prophylactic efficacy of the EpiVacCorona peptide vaccine for COVID-19 prevention (phase III)","volume":"11","author":"Ryzhikov","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib220","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3390\/vaccines10050702","article-title":"A bivalent COVID-19 vaccine based on alpha and beta variants elicits potent and broad immune responses in mice against SARS-CoV-2 variants","volume":"10","author":"Wang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib221","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jinf.2022.11.008","article-title":"Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: a randomized, double-blinded, placebo-controlled, phase I clinical trial","volume":"86","author":"Wang","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102195","article-title":"Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial","volume":"64","author":"Hannawi","year":"2023","journal-title":"EclinicalMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib223","unstructured":"YuD. China grants emergency use of new vaccines as it eases COVID-19 policy, BioWorld 2022, www.bioworld.com\/articles\/692398-china-grants-emergency-use-of-new-vaccines-as-it-eases-covid-19-policy?v=preview (accessed on May 24, 2023)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib224","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/22221751.2022.2056524","article-title":"A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates","volume":"11","author":"An","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib225","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomized, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib226","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","article-title":"Efficacy and safety of the RBD-dimer-based Covid-19 vaccine ZF2001 in adults","volume":"386","author":"Dai","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib227","unstructured":"LiuR. China IMCAS\u2019s COVID-19 vaccine obtained emergency use approval in China. www.reuters.com (accessed on May 24, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib228","unstructured":"MamatlukovM. Uzbekistan approves Chinese-developed COVID-19 vaccine. \u3008www.reuters.com\u3009 (accessed on May 24, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib229","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nbt.2022.08.002","article-title":"An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen","volume":"72","author":"Limonta-Fern\u00e1ndez","year":"2022","journal-title":"N Biotechnol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib230","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101383","article-title":"Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomized, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)","volume":"46","author":"Hern\u00e1ndez-Bernal","year":"2022","journal-title":"EclinicalMedicine"},{"issue":"2023","key":"10.1016\/bs.pmbts.2024.12.002_bib231","article-title":"A phase 3, randomized, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study)","volume":"21","author":"Hern\u00e1ndez-Bernal","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib232","unstructured":"Reuters. Cuban drug regulator gives emergency approval to Abdala COVID-19 vaccine. Available online: Cuban drug regulator gives emergency approval to Abdala COVID-19 vaccine. www.reuters.com\/world\/americas\/cuban-drug-regulator-gives-emergency-approval-abdala-covid-19-vaccine-2021\u201307-09\/, (accessed on May 27, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib233","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1080\/21645515.2021.1901545","article-title":"SARS\u2011CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice","volume":"17","author":"Pollet","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib234","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104217","article-title":"Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomized phase-1\/2 and phase-2 clinical trials","volume":"83","author":"Thuluva","year":"2022","journal-title":"EbioMedicine"},{"issue":"2023","key":"10.1016\/bs.pmbts.2024.12.002_bib235","doi-asserted-by":"crossref","first-page":"2203632","DOI":"10.1080\/21645515.2023.2203632","article-title":"Immunogenicity and safety of biological E\u2019s CORBEVAX\u2122 vaccine compared to COVISHIELD\u2122 (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial","volume":"19","author":"Thuluva","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib236","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1126\/science.abq7229","article-title":"India\u2019s speedy vaccine approvals come under fire","volume":"376","author":"Pulla","year":"2022","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib237","unstructured":"Mguni M. Botswana Approves Corbevax Covid Vaccine, Plans Local Output. www.bloomberg.com (accessed on May 28, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib238","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/acschembio.1c00272","article-title":"SARS-CoV-2 RBD-tetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies","volume":"16","author":"Valdes-Balbin","year":"2021","journal-title":"ACS Chem Biol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib239","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijid.2022.11.016","article-title":"Open-label phase I\/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children","volume":"126","author":"Puga-G\u00f3mez","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib240","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10302","article-title":"Efficacy and safety of a protein-based SARS-CoV-2 vaccine: a randomized clinical trial","volume":"6","author":"Mostafavi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib241","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1080\/22221751.2022.2140608","article-title":"A novel RBD-protein\/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib242","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157707","article-title":"A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants","volume":"132","author":"Wang","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib243","article-title":"A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques","author":"Jiaping","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib244","unstructured":"J.R. Technology. The Philippines Has Approved ReCOV For Phase II\/III Cinical Research. Available online: https:\/\/www.recbio.cn\/en\/media\/press-release\/the-philippines-has-approved-recov-for-phase-iiiii-cinical-research\/ (accessed on May 28, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib245","unstructured":"J.R. Technology, Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia. Available online: https:\/\/www.recbio.cn\/en\/media\/press-release\/20230320\/ (accessed on May 28, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib246","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice","volume":"12","author":"Tian","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib247","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib248","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/cid\/ciac803","article-title":"Safety and efficacy of the NVX-CoV2373 Coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial","volume":"76","author":"Heath","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib249","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.936523","article-title":"Editorial: first approval of the protein-based adjuvanted nuvaxovid (NVX-CoV2373) novavax vaccine for SARS-CoV-2 could increase vaccine uptake and provide immune protection from viral variants","volume":"28","author":"Parums","year":"2022","journal-title":"Med Sci Monit"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib250","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41541-023-00622-0","article-title":"Immunogenicity and protective efficacy of GBP510\/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques","volume":"8","author":"Jacob-Dolan","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib251","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101569","article-title":"Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a randomized, placebo-controlled, observer-blinded phase 1\/2 trial","volume":"51","author":"Song","year":"2022","journal-title":"EclinicalMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib252","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102140","article-title":"Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomized, active-controlled, observer-blinded, phase 3 trial","volume":"64","author":"Song","year":"2023","journal-title":"EclinicalMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib253","doi-asserted-by":"crossref","first-page":"328","DOI":"10.53854\/liim-2903-3","article-title":"Review of COVID-19 viral vector-based vaccines and COVID-19 variants","volume":"29","author":"Vanaparthy","year":"2021","journal-title":"Infez Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib254","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/v13020317","article-title":"Viral vectors for COVID-19 vaccine development","volume":"13","author":"Lundstrom","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib255","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib256","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomized controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib257","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib258","unstructured":"UK, G.O.V. Regulatory approval of COVID-19 vaccine AstraZeneca. GOV. UK 2021."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib259","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1038\/s41467-020-17972-1","article-title":"A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib260","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib261","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a 43andomized, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib262","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","volume":"399","author":"Halperin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib263","unstructured":"China Approves Two More Domestic COVID-19 Vaccines for Public Use. Available online: https:\/\/www.reuters.com\/article\/idUSKBN2AP1V8\/ (accessed on May 29, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib264","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"Npj Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib265","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine","volume":"2021","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib266","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa2117608","article-title":"Final analysis of efficacy and safety of single-dose Ad26.COV2.S","volume":"386","author":"Sadoff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib267","unstructured":"Food and Drug Administration. Fact Sheet for Healthcare Providers Administrating Vaccine (Vaccination Providers), Emergency Use Authorization (EUA) of the Janssen COVID-19 Vaccine to Prevent Coronavirus Disease (COVID-19); Food and Drug Administration: Silver Spring, MD, USA, 2019. Available online: https:\/\/www.fda.gov\/media\/146304\/download (accessed on May 30, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib268","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S1473-3099(20)30709-X","article-title":"The arrival of Sputnik V","volume":"20","author":"Balakrishnan","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib269","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomized phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib270","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib271","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/d41586-020-02386-2","article-title":"Russia\u2019s fast-track coronavirus vaccine draws outrage over safety","volume":"584","author":"Callaway","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib272","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.ymthe.2021.04.022","article-title":"Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19","volume":"29","author":"Capone","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib273","doi-asserted-by":"crossref","first-page":"eabj1996","DOI":"10.1126\/scitranslmed.abj1996","article-title":"GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults","volume":"14","author":"Lanini","year":"2022","journal-title":"Sci Transl Med"},{"issue":"2021","key":"10.1016\/bs.pmbts.2024.12.002_bib274","first-page":"e02260","article-title":"COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice","volume":"95","author":"Garc\u00eda-Arriaza","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib275","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3390\/vaccines9101208","article-title":"Characterization of individuals interested in participating in a phase I SARS-CoV-2 vaccine trial","volume":"9","author":"Shamsrizi","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib276","unstructured":"COVID-19 Trial of the Candidate Vaccine MVA-SARS-2-S in Adults. Available online: https:\/\/www.clinicaltrials.gov\/NCT05950 776 (accessed on May 30, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib277","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/vaccines8040771","article-title":"A newcastle disease virus (NDV) expressing a membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine","volume":"8","author":"Sun","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib278","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4103\/njms.njms_454_21","article-title":"Review of current vaccine development platform to prevent coronavirus disease","volume":"13","author":"Arif","year":"2022","journal-title":"Natl J Maxillofac Surg"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib279","unstructured":"Immunity and Safety of COVID-19 Synthetic Minigene Vaccine. Available online: https:\/\/www.clinicaltrials.gov\/NCT04276896 (accessed on May 30, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib280","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3390\/v12090987","article-title":"Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice","volume":"12","author":"Loes","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib281","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S2213-2600(22)00131-X","article-title":"Safety and immunogenicity of a liveattenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"10","author":"Zhu","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib282","doi-asserted-by":"crossref","first-page":"11371","DOI":"10.1073\/pnas.93.21.11371","article-title":"Alphavirus-based expression vectors: strategies and applications","volume":"93","author":"Frolov","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib283","doi-asserted-by":"crossref","first-page":"32657","DOI":"10.1073\/pnas.2014468117","article-title":"A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine","volume":"117","author":"H\u00f6rner","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib284","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103810","article-title":"Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591\/TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study","volume":"75","author":"Launay","year":"2022","journal-title":"EbioMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib285","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib286","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104138","article-title":"Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial","volume":"82","author":"Robbins","year":"2022","journal-title":"EbioMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib287","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1038\/s41467-020-20228-7","article-title":"A single dose of recombinant VSV-\u2206G-spike vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Yahalom-Ronen","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib288","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/vaccines10020291","article-title":"Neutralization of SARS-CoV-2 variants by rVSV-\u2206G-spike-elicited human sera","volume":"10","author":"Yahalom-Ronen","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib289","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13567-019-0698-z","article-title":"Recent advances in delivery of veterinary DNA vaccines against avian pathogens","volume":"50","author":"Jazayeri","year":"2019","journal-title":"Vet Res"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib290","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/cbin.11155","article-title":"Nuclear delivery of plasmid DNA determines the efficiency of gene expression","volume":"43","author":"Liu","year":"2019","journal-title":"Cell Biol Int"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib291","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib292","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib293","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/infdis\/jiac016","article-title":"SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial","volume":"225","author":"Kraynyak","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib294","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure","author":"Mammen","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib295","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1016\/j.vaccine.2021.05.098","article-title":"Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models","volume":"39","author":"Dey","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib296","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101020","article-title":"Safety and immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India","volume":"38","author":"Momin","year":"2021","journal-title":"EclinicalMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib297","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomized, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib298","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/d41586-021-02385-x","article-title":"India\u2019s DNA COVID vaccine is a world first\u2014more are coming","volume":"597","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib299","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/vaccines9040307","article-title":"Soluble spike DNA vaccine provides long-term protective immunity against SARS-CoV-2 in mice and nonhuman primates","volume":"9","author":"Seo","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib300","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S2666-5247(21)00358-X","article-title":"Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults","volume":"3","author":"Ahn","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib301","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1038\/s41598-021-82498-5","article-title":"DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice","volume":"11","author":"Szurgot","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib302","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.3390\/ijms24065944","article-title":"mRNA vaccines against SARS-CoV-2: advantages and caveats","volume":"24","author":"Echaide","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib303","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib304","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib305","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Polack","year":"2021","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib306","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: First approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib307","unstructured":"FDA Approves First COVID-19 Vaccine. Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-covid-19-vaccine (accessed on May 31, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib308","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib309","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2-preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib310","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib311","unstructured":"FDA Takes Additional Action in Fight against COVID-19 by Issuing Emergency Use Authorization for Second COVID-19 Vaccine. Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid (accessed on May 31, 2024)."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib312","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41541-021-00311-w","article-title":"mRNA-based SARS-CoV-2 vaccine candidate CvnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents","volume":"6","author":"Rauch","year":"2021","journal-title":"Npj Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib313","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00508-021-01922-y","article-title":"Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: a phase 1 randomized clinical trial","volume":"133","author":"Kremsner","year":"2021","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib314","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1093\/cid\/ciac075","article-title":"Relating in vitro neutralization level and protection in the CvnCoV (CUREVAC) trial","volume":"75","author":"Cromer","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib315","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib316","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41392-021-00861-4","article-title":"Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib317","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2666-5247(21)00280-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomized, double-blind, placebo-controlled, phase 1 trial","volume":"3","author":"Chen","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib318","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib319","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101262","article-title":"Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial","volume":"44","author":"Pollock","year":"2022","journal-title":"EclinicalMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib320","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101823","article-title":"COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2","volume":"56","author":"Szubert","year":"2023","journal-title":"EclinicalMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib321","article-title":"mRNA-based COVID-19 vaccine booster dose: benefits, risks, and coverage","volume":"93","author":"Nashwan","year":"2022","journal-title":"Acta Biomed"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib322","unstructured":"LundstromK. Role of Nucleic Acid Vaccines for the Management of Emerging Variants of SARS-CoV-2. In SARS-CoV-2 Variants and Global Population: Diagnostic Strategies, Vaccine Development, and Therapeutic Management. V.P. Chavda, V.N. Uversky (Eds.). Apple Academic Press, Inc."},{"key":"10.1016\/bs.pmbts.2024.12.002_bib323","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jinf.2023.06.022","article-title":"Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine VLA2001: a randomized, controlled, phase 3COV-COMPARE trial","volume":"87","author":"Taucher","year":"2003","journal-title":"J Infect"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib324","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102109","article-title":"Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study","volume":"62","author":"De Bruyn","year":"2023","journal-title":"EclinicalMedicine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib325","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","volume":"20","author":"Zeng","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib326","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1016\/j.vaccine.2022.04.041","article-title":"Covax-19\/Spikogen\u00ae vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single does protection against SASR-CoV-2 infection in hamsters","volume":"40","author":"Li","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib327","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41541-023-00693-z","article-title":"Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants","volume":"8","author":"Lyke","year":"2023","journal-title":"Npj Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib328","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s43440-022-00429-1","article-title":"Efficacy of COVID-19 vaccines: a systematic review and network meta-analysis of phase 3 randomized controlled trials","volume":"74","author":"Kumar","year":"2022","journal-title":"Pharmacol Rep"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib329","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/infdis\/jiac241","article-title":"High neutralizing antibody levels against severe acute respiratory syndrome Coronavirus 2 Omicron BA.1 and BA.2 after UB-612 vaccine booster","volume":"226","author":"Guirakhoo","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib330","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib331","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1056\/NEJMoa2116597","article-title":"Effect of COVID-19 vaccination on transmission of alpha and delta variants","volume":"386","author":"Eyre","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib332","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03681-2","article-title":"Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans","volume":"596","author":"Alter","year":"2021","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib333","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01538-22","article-title":"Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice","volume":"10","author":"Gonzalez-Dominguez","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib334","article-title":"SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus","volume":"9","author":"Wang","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009064","article-title":"Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: protection of mice after a single immunization","volume":"17","author":"Hennrich","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib336","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41541-021-00384-7","article-title":"INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants","volume":"6","author":"Andrade","year":"2021","journal-title":"Npj Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib337","article-title":"Design, immunogenicity and efficacy of a Pan-SARS-CoV-2 synthetic DNA vaccine","author":"Reed","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib338","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.vaccine.2022.03.060","article-title":"Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates","volume":"40","author":"Walters","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib339","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib340","first-page":"2100894","article-title":"Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021","volume":"26","author":"Mart\u0131nez-Baz","year":"2021","journal-title":"Eurosurveillance"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib341","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMc2113864","article-title":"BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant","volume":"385","author":"Sheikh","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib342","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063935","article-title":"Effectiveness of mRNA COVID-19 Vaccines against Omicron and Delta Variants in a matched test-negative case-control study among US veterans","volume":"12","author":"Young-Xu","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib343","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJMc2202542","article-title":"Efficacy of fourth dose of Covid-19 mRNA vaccines against omicron","volume":"386","author":"Regev-Yochay","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib344","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of prior infection and vaccination on symptomatic omicron infections","volume":"387","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib345","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01313-21","article-title":"Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants","volume":"95","author":"Choi","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib346","article-title":"mRNA-1273 vaccine-elicited neutralization of SARS-CoV-2 omicron in adolescents and children","author":"Girard","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib347","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against COVID-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib348","article-title":"XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2","author":"Wang","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib349","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/vaccines10040508","article-title":"A third dose of the COVID-19 vaccine, CvnCoV, increased the neutralizing activity against the SARS-CoV-2 wild-type and delta variant","volume":"10","author":"Wolz","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib350","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1016\/j.vaccine.2022.03.064","article-title":"A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model","volume":"40","author":"Frise","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib351","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.ymthe.2022.04.014","article-title":"A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T Cell-mediated immunity","volume":"30","author":"McCafferty","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib352","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41541-022-00578-7","article-title":"Author correction: a self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability","volume":"7","author":"Voigt","year":"2022","journal-title":"Npj Vaccines"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib353","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","volume":"20","author":"Zeng","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/bs.pmbts.2024.12.002_bib354","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"}],"container-title":["Progress in Molecular Biology and Translational Science","Navigating the Complexities of SARS-CoV-2 Immunobiology: The Science Behind the COVID-19 Pandemic"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117324002199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117324002199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T15:35:16Z","timestamp":1744731316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117324002199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443238321"],"references-count":353,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2024.12.002","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}